Jefferies Group’s Adverum Biotechnologies ADVM Stock Holding History

Jefferies Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-730	Closed	-$119K	–	2224
2015 Q2	$119K	Buy	+730	New	+$246K	﹤0.01%	2142

Other funds holding ADVM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jefferies Group's ADVM Position: Q1 2020 in Review

Jefferies Group sold out of Adverum Biotechnologies (ADVM) in Q1 2020, closing a stake of 1,788 shares — an estimated $206K sold.

Jefferies Group first reported a position in ADVM in Q2 2015 and held it in 6 quarters. The position peaked at $476K in Q4 2015. 126 funds tracked by Wall St. Rank hold ADVM as of Q1 2020.

Jefferies Group reported no remaining Adverum Biotechnologies position as of Q1 2020 after selling out during the quarter.
Jefferies Group sold 1,788 Adverum Biotechnologies shares in Q1 2020, an estimated $206K.
Jefferies Group first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 6 quarters.
Jefferies Group's Adverum Biotechnologies position peaked at $476K in Q4 2015.
126 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2020.

Based on Jefferies Group's 13F filing for Q1 2020, filed 15 May 2020.